- Home
- ANIX vs LRE Comparison
ANIX vs LRE Comparison
Compare ANIX & LRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- LRE
- Stock Information
- Founded
- ANIX 1982
- LRE 2001
- Country
- ANIX United States
- LRE Japan
- Employees
- ANIX N/A
- LRE N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- LRE
- Sector
- ANIX Health Care
- LRE
- Exchange
- ANIX Nasdaq
- LRE Nasdaq
- Market Cap
- ANIX 108.9M
- LRE 24.4M
- IPO Year
- ANIX 1987
- LRE 2023
- Fundamental
- Price
- ANIX $3.17
- LRE $1.80
- Analyst Decision
- ANIX Strong Buy
- LRE
- Analyst Count
- ANIX 3
- LRE 0
- Target Price
- ANIX $9.00
- LRE N/A
- AVG Volume (30 Days)
- ANIX 126.1K
- LRE 9.3K
- Earning Date
- ANIX 09-05-2025
- LRE 01-01-0001
- Dividend Yield
- ANIX N/A
- LRE N/A
- EPS Growth
- ANIX N/A
- LRE N/A
- EPS
- ANIX N/A
- LRE N/A
- Revenue
- ANIX N/A
- LRE $110,330,328.00
- Revenue This Year
- ANIX N/A
- LRE N/A
- Revenue Next Year
- ANIX N/A
- LRE N/A
- P/E Ratio
- ANIX N/A
- LRE N/A
- Revenue Growth
- ANIX N/A
- LRE 3.92
- 52 Week Low
- ANIX $2.07
- LRE $1.10
- 52 Week High
- ANIX $4.20
- LRE $2.49
- Technical
- Relative Strength Index (RSI)
- ANIX 48.74
- LRE 57.95
- Support Level
- ANIX $3.18
- LRE $1.72
- Resistance Level
- ANIX $3.24
- LRE $1.78
- Average True Range (ATR)
- ANIX 0.14
- LRE 0.08
- MACD
- ANIX -0.04
- LRE -0.01
- Stochastic Oscillator
- ANIX 21.05
- LRE 36.73
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.